Original Research

Published on 02 Nov 2023

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma

in Hematologic Malignancies

Laura Rosiñol
Benjamin Hebraud
Albert Oriol
Anne-Laurène Colin
Rafael Ríos Tamayo
Cyrille Hulin
María Jesús Blanchard
Denis Caillot
Anna Sureda
Miguel Teodoro Hernández

Frontiers in Oncology

doi 10.3389/fonc.2023.1197340

2,780 views
5 citations

Case Report

Published on 01 Nov 2023

An adolescent with primary cutaneous follicle center lymphoma: a case report and literature review

in Hematologic Malignancies

Wen-Yan Niu
Xue-Shen Yan
Han Qiao
Yu-Jiao Sun
Hai-Yan Gu
Guang-Lun Li
Zhong-Guang Cui
Juan Du

Frontiers in Oncology

doi 10.3389/fonc.2023.1273719

1,150 views
1 citation

Case Report

Published on 01 Nov 2023

Case Report: A novel FGFR1 fusion in acute B-lymphoblastic leukemia identified by RNA sequencing

in Hematologic Malignancies

Zhibo Zhang
Yiyan Zhu
Zheng Wang
Zhao Zeng
Lijun Wen
Ling Zhang
Suning Chen

Frontiers in Oncology

doi 10.3389/fonc.2023.1276695

1,489 views
2 citations

Original Research

Published on 01 Nov 2023

Impact of different chemotherapy regimens on intestinal mucosal injury assessed with bedside ultrasound: a study in 213 AML patients

in Hematologic Malignancies

Edoardo Benedetti
Ginevra Traverso
Giulia Pucci
Riccardo Morganti
Emilia Bramanti
Piero Lippolis
Maria Chiara Susini
Elisa Mazzantini
Rachele Giubbolini
Fabrizio Mavilia

Frontiers in Oncology

doi 10.3389/fonc.2023.1272072

2,056 views
1 citation

Original Research

Published on 30 Oct 2023

Analysis of redox status and HDL subclasses in patients with lymphoma and the associations with FDG-PET/CT findings

in Hematologic Malignancies

Bosa Mirjanic-Azaric
Sinisa Stankovic
Lana Nezic
Zana Radic Savic
Dragana Malcic- Zanic
Ranko Skrbic
Jelena Kotur-Stevuljevic
Natasa Bogavac-Stanojevic

Frontiers in Oncology

doi 10.3389/fonc.2023.1221414

1,283 views
1 citation

Original Research

Published on 25 Oct 2023

Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)

in Hematologic Malignancies

Ga-Young Song
Je-Jung Lee
Joon Ho Moon
Dajung Kim
Min Kyoung Kim
Hyo Jung Kim
Yeung-Chul Mun
Won-Sik Lee
Young Rok Do
Jae Hoon Lee

Frontiers in Oncology

doi 10.3389/fonc.2023.1209110

2,058 views

Original Research

Published on 25 Oct 2023

Exploring the cell-free total RNA transcriptome in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma patients as biomarker source in blood plasma liquid biopsies

in Hematologic Malignancies

Philippe Decruyenaere
Edoardo Giuili
Kimberly Verniers
Jasper Anckaert
Katrien De Grove
Malaïka Van der Linden
Dries Deeren
Jo Van Dorpe
Fritz Offner
Jo Vandesompele

Frontiers in Oncology

doi 10.3389/fonc.2023.1221471

3,443 views
2 citations

Original Research

Published on 24 Oct 2023

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling

in Hematologic Malignancies

Kathrin Olschok
Bianca Altenburg
Marcelo A. S. de Toledo
Angela Maurer
Anne Abels
Fabian Beier
Deniz Gezer
Susanne Isfort
Katrin Paeschke
Tim H. Brümmendorf

Frontiers in Oncology

doi 10.3389/fonc.2023.1277453

4,589 views
5 citations

Original Research

Published on 24 Oct 2023

Management and clinical outcomes of follicular lymphoma across continuous lines of treatments: a retrospective analysis in China

in Hematologic Malignancies

Jiaxin Liu
Yunfei Hu
Linjun Zhao
Reyizha Nuersulitan
Yanfei Liu
Hui Yu
Yingying Ye
Dedao Wang
Yongjing Tang
Feier Feng

Frontiers in Oncology

doi 10.3389/fonc.2023.1264723

2,549 views

Case Report

Published on 24 Oct 2023

The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review

in Hematologic Malignancies

Witold Prejzner
Oliwia Piekoś
Karolina Bełdzińska
Alicja Sadowska-Klasa
Ewa Zarzycka
Maria Bieniaszewska
Krzysztof Lewandowski
Jan Maciej Zaucha

Frontiers in Oncology

doi 10.3389/fonc.2023.1228481

4,385 views
2 citations

Addendum

Published on 20 Oct 2023

Addendum: B-cell lymphoblastic lymphoma following intravenous BNT162b2 mRNA booster in a BALB/c mouse: a case report

in Hematologic Malignancies

Sander Eens
Manon Van Hecke
Kasper Favere
Thomas Tousseyn
Pieter-Jan Guns
Tania Roskams
Hein Heidbuchel

Frontiers in Oncology

doi 10.3389/fonc.2023.1267904

3,312 views

Review

Published on 20 Oct 2023

Hepatitis B Virus and B-cell lymphoma: evidence, unmet need, clinical impact, and opportunities

in Hematologic Malignancies

Maya Rosenberg
Maria Poluch
Colin Thomas
Paola Sindaco
Alan Khoo
Pierluigi Porcu

Frontiers in Oncology

doi 10.3389/fonc.2023.1275800

3,724 views
5 citations

Case Report

Published on 20 Oct 2023

Case Report: Treatment of the rare B-cell lymphoblastic lymphoma with scalp lesion using rotation flap

in Hematologic Malignancies

Timothy Kim
Geena Jung
Emery Buckner-Wolfson
Ryan Fatemi
Genesis Liriano
Adit Tal
Yanhua Wang
Oren Tepper
Andrew Kobets

Frontiers in Oncology

doi 10.3389/fonc.2023.1252512

2,283 views

Case Report

Published on 18 Oct 2023

Case report: Successful treatment of refractory immune thrombocytopenia in chronic lymphocytic leukaemia with venetoclax monotherapy

in Hematologic Malignancies

Timothy Woo
Matthew Carter
George Follows
Piers EM. Patten

Frontiers in Oncology

doi 10.3389/fonc.2023.1260003

2,257 views
1 citation

Review

Published on 17 Oct 2023

Checkpoint inhibition in hematologic malignancies

in Hematologic Malignancies

Aaron Tsumura
Daniel Levis
Joseph M. Tuscano

Frontiers in Oncology

doi 10.3389/fonc.2023.1288172

3,554 views
2 citations

Original Research

Published on 16 Oct 2023

Prognostic significance of the systemic immune-inflammation index in patients with extranodal natural killer/T-cell lymphoma

in Hematologic Malignancies

Tao Hai
Wanchun Wu
Kexin Ren
Na Li
Liqun Zou

Frontiers in Oncology

doi 10.3389/fonc.2023.1273504

7,426 views

Navigation group

Articles

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma

An adolescent with primary cutaneous follicle center lymphoma: a case report and literature review

Case Report: A novel FGFR1 fusion in acute B-lymphoblastic leukemia identified by RNA sequencing

Impact of different chemotherapy regimens on intestinal mucosal injury assessed with bedside ultrasound: a study in 213 AML patients

Analysis of redox status and HDL subclasses in patients with lymphoma and the associations with FDG-PET/CT findings

Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)

Exploring the cell-free total RNA transcriptome in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma patients as biomarker source in blood plasma liquid biopsies

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling

Management and clinical outcomes of follicular lymphoma across continuous lines of treatments: a retrospective analysis in China

The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review

Addendum: B-cell lymphoblastic lymphoma following intravenous BNT162b2 mRNA booster in a BALB/c mouse: a case report

Hepatitis B Virus and B-cell lymphoma: evidence, unmet need, clinical impact, and opportunities

Case Report: Treatment of the rare B-cell lymphoblastic lymphoma with scalp lesion using rotation flap

Case report: Successful treatment of refractory immune thrombocytopenia in chronic lymphocytic leukaemia with venetoclax monotherapy

Checkpoint inhibition in hematologic malignancies

Prognostic significance of the systemic immune-inflammation index in patients with extranodal natural killer/T-cell lymphoma